ProRx — Exton

ProRx LLC has initiated a Class II recall of 2,649 vials of Semaglutide Injection (2.5mg/1mL) due to a lack of sterility assurance. This marks the second sterility-related recall for ProRx LLC in just over a year, raising significant concerns for procurement and regulatory teams regarding supply chain reliability and patient safety from compounded products.

ProRx LLC has initiated a Class II recall of 8,310 vials of Semaglutide Injection due to a lack of sterility assurance, impacting distribution in Texas and Utah. This marks the second sterility-related recall for ProRx LLC's compounded injectables within a year, following a Tirzepatide recall in 2024. Procurement and regulatory teams must immediately assess supply chain exposure and re-evaluate ProRx LLC's reliability as a sterile drug manufacturer.

ProRx LLC has initiated a nationwide Class II recall of 37 vials of compounded Tirzepatide injection from its Exton, PA facility, citing a lack of assurance of sterility. This event underscores critical quality control vulnerabilities in sterile compounding, necessitating immediate review of supplier qualification processes and robust quality assurance protocols for procurement and regulatory teams.